3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
40
Cisplatin
25
Fluorouracil
24
Paclitaxel
21
Oxaliplatin
16
Capecitabine
12
Leucovorin
10
Irinotecan
10
Docetaxel
10
Gemcitabine
8
Carboplatin
7
atezolizumab
6
Nivolumab
6
Bevacizumab
6
Trastuzumab
5
Ramucirumab
5
Radiotherapy
5
spartalizumab
4
Albumin-Bound Paclitaxel
4
zanidatamab
3
tisotumab vedotin
3
patritumab deruxtecan
3
lenvatinib
3
fludarabine
3
durvalumab
3
Radiation
3
Drug Therapy
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Neoplasms
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled